The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
News|Articles|November 15, 2018
- Pharmaceutical Technology-11-15-2018
- Volume 2018 eBook
- Issue 2
Mixed Reality Gains a Foothold in the Lab
Author(s)Agnes Shanley
Rather than isolating the user in a virtual world, mixed reality allows contextualized data to be shared in real time, improving assays, standard operating procedures, workflows, and overall tech transfer.
Advertisement
Augmented or mixed reality offers benefits in tech transfer, general batch recordkeeping and SOPs, and training, especially the transmission of “tribal knowledge” that cannot be put in a training manual. Now that augmented reality hardware has sufficiently advanced, use of the technology is starting to take off in pharma. Apprentice.io is focusing on pharma and biotech applications. The company’s CEO and cofounder Anthony Stracquatanio discusses trends.
Article Details
Pharmaceutical Technology
eBook: Bio/Pharma Laboratory Best Practices 2018
Vol. 42
November 2018
Pages: 8–9
Citation
When referring to this article, please cite it as A. Shanley, "Mixed Reality Gains a Foothold in the Lab," Pharmaceutical Technology Bio/Pharma Laboratory Best Practices eBook (November 2018).
Articles in this issue
almost 8 years ago
Precompetitive Research Spurs Innovation in Pharmaceutical Analysisalmost 8 years ago
Cobots in the Pharma Labalmost 8 years ago
Analytical Best Practices for Raw Materials Testingalmost 8 years ago
Complex Protein Studies Demand Dynamic Techniquesalmost 8 years ago
Barriers and Solutions to Effective External Collaboration in Biopharmaalmost 8 years ago
Best Practices in Analytical Method Development and TestingAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement